biological source
Porcine intestinal mucosa
Quality Level
form
powder
specific activity
≥180 USP units/mg
solubility
H2O: 50 mg/mL, clear, colorless to faintly yellow
cation traces
Ca: ≤20 ppm
storage temp.
2-8°C
SMILES string
[Na+].[S](=O)(=O)(NC1C(OC(C(C1O[S](=O)(=O)O)OC4OC(C(C(C4O[S](=O)(=O)O)O)O)C(=O)O)CO)OC2C(OC(C(C2O)O[S](=O)(=O)O)OC3C(OC(C(C3O)NC(=O)C)O)CO[S](=O)(=O)O)C(=O)O)O
InChI key
JRTRSJGZMRQDHI-UHFFFAOYSA-N
General description
Our comprehensive portfolio of downstream process chemicals not only provides biopharmaceutical manufacturers with high-quality raw materials for production of classical and novel therapies, but also helps them get to market faster and simplify regulatory challenges. Ranging from non-GMP grades for low-risk application, to IPEC-PQG GMP for higher-risk applications, we have products covering all your manufacturing needs.
Analysis Note
Low calcium content
저장 등급
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
문서
Glycosaminoglycans are large linear polysaccharides constructed of repeating disaccharide units.
Linda Cruz et al.
PloS one, 8(7), e68379-e68379 (2013-07-19)
Human papillomavirus (HPV) infection is the leading cause of cervical cancer world-wide. Here, we show that native HPV particles produced in a differentiated epithelium have developed different strategies to infect the host. Using biochemical inhibition assays and glycosaminoglycan (GAG)-negative cells
Eve Draper et al.
PloS one, 8(5), e61825-e61825 (2013-05-08)
The current generation of Human Papillomavirus (HPV) vaccines, Cervarix® and Gardasil®, exhibit a high degree of efficacy in clinical trials against the two high-risk (HR) genotypes represented in the vaccines (HPV16 and HPV18). High levels of neutralizing antibodies are elicited
Felix J Hartmann et al.
Cell reports, 28(3), 819-831 (2019-07-18)
The success of immunotherapy has led to a myriad of clinical trials accompanied by efforts to gain mechanistic insight and identify predictive signatures for personalization. However, many immune monitoring technologies face investigator bias, missing unanticipated cellular responses in limited clinical